Minesapride

Minesapride is a more recent addition to the selective 5-HT4 prokinetic class, a benzamide-derived partial agonist with high affinity for the 5-HT4 receptor developed for constipation-predominant irritable bowel syndrome in Japan.

In a double-blind phase 2 study of 171 patients with Rome III-defined constipation-predominant irritable bowel syndrome, minesapride at doses up to 40 mg once daily increased the weekly frequency of complete spontaneous bowel movements relative to placebo, improved abdominal symptom scores at the highest dose, and reduced the overall irritable bowel severity index, with the 12 mg and 40 mg doses producing the largest reductions; treatment-emergent adverse events were similar between minesapride and placebo, and diarrhea was the most common ^[1]. This established minesapride as an active and generally well-tolerated prokinetic.

Cardiac safety was a specific focus given the history of the benzamide class. A thorough QT/QTc study in healthy Japanese adults administered therapeutic 40 mg and supratherapeutic 120 mg single doses and found no association with QT-interval prolongation, distinguishing minesapride from cisapride while noting that some benzamides such as mosapride are likewise QT-neutral ^[2]. Reviews of the luminal and enteric actions of 5-HT4 receptor agonists provide the mechanistic backdrop for how such agents drive propulsive colonic motor patterns ^[3].

In its phase 2 trial the rate of treatment-emergent adverse events with minesapride was comparable to placebo, with diarrhea the most frequent effect, consistent with its prokinetic mechanism. A thorough QT/QTc study found no increased risk of QT-interval prolongation at therapeutic or supratherapeutic doses, directly addressing the cardiac liability that ended cisapride's use. As an investigational agent still in development, its long-term safety across broad populations has not been fully established.

Minesapride, coded DSP-6952, was developed by Sumitomo Dainippon Pharma as part of continued interest in selective 5-HT4 agonists for functional gastrointestinal disorders, with clinical studies conducted principally in Japan in the 2010s. Its phase 2 efficacy trial and thorough QT study, reported around 2020, positioned it as a modern, cardiac-safe benzamide prokinetic for constipation-predominant irritable bowel syndrome, at a time when treatment options for that subtype remained limited. It is a relatively new member of the class.

Minesapride is regarded as a promising, well-tolerated, and cardiac-safe selective 5-HT4 agonist within the specialized gastroenterology literature, though it is less widely known than prucalopride or tegaserod and its development has been centred in Japan. It is cited as an example of the continuing refinement of benzamide prokinetics for irritable bowel syndrome. It has no nootropic profile, being a peripheral gut agent.